New approaches to fill the methods gap in pharmacovigilance

More documents

Recommendations

Info

30Take home messages
Take home messages Active risk management needs more time to ‘infiltrate’ thewhole ‘drug landscape’31
Page 5: The pharmacovigilance ‘tool kit
Page 8 and 9: European Medicines Agency prioritie
Page 10 and 11: 10Struggle 1: long-term adverse eff
Page 12 and 13: Benefit-risk balance at time of app
Page 14 and 15: How to perform long-term follow-up?
Page 16 and 17: Limitations of registries Comparato
Page 18 and 19: Studying long-term effects in datab
Page 20 and 21: 20Struggle 2: drug-induced malignan
Page 22 and 23: 22Struggle 2: drug-induced malignan
Page 24 and 25: Insuline glargine and cancer risk 4
Page 26 and 27: Investors are reacting promptly tor
Page 28 and 29: 28European Medicines Agengy conclus
Page 32 and 33: Take home messages Active risk mana
Page 34: 34Thank you for your attention

New approaches to fill the methods gap in pharmacovigilance

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?